CClinicalTrials.gg
CompletedNCT03905356EXERTUpdated May 6, 2023

Exercise Therapy in Radiation Therapy

An interventional study of Exercise Therapy in Metastatic Cancer, sponsored by Milton S. Hershey Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate exercise therapy as a method for potentially improving radiation therapy treatment toxicities for metastatic cancer patients receiving radiation therapy.

Read the detailed description

Study Objectives and Endpoints:

Aim 1. To determine the acceptability, feasibility, and safety of an exercise intervention among cancer patients receiving radiation therapy. The investigators anticipate that >25% of approached patients will consent to the protocol; >33% of eligible radiation therapy patients who consent will perform the exercise prescribed (based on the response rate from EnACT); and \<25% of participants will experience a musculoskeletal impairment (without treatment alterations) and \<5% will experience a musculoskeletal injury with symptoms lasting ≥ week or requiring medical attention. The investigators' approach will be to include patients receiving definitive RT; excluding patients at high risk for side effects from combination therapy, including fracture or cardiovascular events.

Aim 2. To discern the clinical outcomes of patients receiving RT+ET. The hypothesis is that adding ET to RT will improve patient reported outcomes and physical functioning. The investigators' approach will be to use standardized questionnaires and assessment tools: patient reported outcomes will be assessed using Common Terminology Criteria for Adverse Events - Patient Reported Outcomes (CTCAE-PROs), loaded onto tablets that patients use in the clinic. Questions will assess global PROs relevant to the ability to tolerate RT, including fatigue, pain, nausea, vomiting; and disease-site-specific PROs, including genitourinary/sexual symptoms for patients receiving pelvic RT. RT dose alterations will be documented. Scores will be compared pre- vs post- RT. The investigators will also use standardized measures already used in EnACT, including grip strength, 30-second chair stand, timed up-and-go, and 4-stage balance. Scores will be compared pre- vs post- RT.

02

Conditions studied

  • Metastatic Cancer

Browse trials for

03

In context

Neoplasm Metastasis

3,517 studies on the registry are indexed under Neoplasm Metastasis; 885 are open to participants now.

This study's enrollment of 16 is below the median of 54 across 2,767 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Milton S. Hershey Medical Center is the lead sponsor of 480 studies on the registry; 61 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 42 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Males and females ≥18 years of age
  • Fluent in written and spoken English
  • Must be able to provide and understand informed consent
  • Must have an ECOG PS of ≤ 2
  • Diagnosed with metastatic disease
  • Cancer patients (stage 1-4)
  • Treatment to primary site or metastatic disease
  • Scheduled to receive radiation therapy at Penn State Cancer Institute
  • Absence of absolute contraindications for exercise according to the American Heart Association (see below)
  • Primary attending oncologist approval
  • Receiving treatment as an outpatient

Exclusion criteria

Exclusion Criteria:

  • Receiving radiation therapy at a location other than Penn State Cancer Institute
  • Not fluent in written and spoken English
  • Evidence in the medical record of an absolute contraindication for exercise
  • Performing > 90 minutes/week of physical activity at the time of initial evaluation
  • Cardiac exclusion criteria:

    • Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
    • History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty or stenting within the past 6 months prior to the start of radiation therapy
    • Uncontrolled arrhythmias; patients with rate controlled atrial fibrillation for >1 month prior to start of radiation therapy may be eligible
    • syncope
    • acute myocarditis, pericarditis, or endocarditis
    • acute pulmonary embolus or pulmonary infarction
    • thrombosis of lower extremities
    • suspected dissecting aneurysm
    • pulmonary edema
    • respiratory failure
    • acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
    • mental impairment leading to inability to cooperate
  • Pregnant women
  • In-patient receiving radiation therapy for a radiation emergency (e.g. cord compression, SVC syndrome, brain metastases)
  • High risk of fracture or spine instability (Mirels score ≥7, SINS ≥7)
  • Children (the protocol will only include individuals 18 and older)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Exercise

    The exercise intervention will utilize the "Moving Through Cancer: A Guide to Exercise for Cancer Survivors" framework. A certified cancer exercise physiologist will work through this guide at radiation therapy visits, with at least 1 visit per week, per the study schema. The cancer exercise physiologist will teach participants proper: warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. The cancer exercise physiologist will tailor the instruction to convey special considerations for exercise based on treatment and cancer type. The patient will perform supervised exercise in the Exercise Medicine Unit under the guidance of the cancer exercise specialist. The exercise done will be educational in nature (i.e. learning about proper walking form, proper intensity for a warmup/cool down, proper techniques for resistance exercises).

    Behavioral: Exercise Therapy

Interventions

  • BehavioralExercise Therapy

    Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.

06

What researchers measure

Primary outcomes

  1. Acceptability of exercise intervention: (number of patients agreeing to perform RT+ET)/(number approached)

    (number of patients agreeing to perform RT+ET)/(number approached)

    Time frame: 1 year

  2. Feasibility of exercise intervention: (number of patients who completed RT+ET)/(number agreeing to perform RT+ET)

    (number of patients who completed RT+ET)/(number agreeing to perform RT+ET)

    Time frame: 1 year

  3. Incidence of Treatment- Emergent Adverse Events

    Safety of exercise intervention: freedom from any Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher event

    Time frame: 1 year

Secondary outcomes

  1. Change in timed up and go

    Timed up and go

    Time frame: 3 Months

  2. change in grip strength

    Grip strength

    Time frame: 3 Months

  3. change in quality of life measured via the Godin Physical Activity Questionnaire

    The Godin Physical Activity Questionnaire asks how much physical activity the participant engages in during a typical 7-day period.

    Time frame: 3 Months

  4. change in quality of life measured via the Barriers to Exercise RM 5-FM survey

    The Barriers to Exercise RM 5-FM survey asks participants about barriers to being active. Response options include: very likely; somewhat likely; somewhat unlikely; very unlikely.

    Time frame: 3 Months

  5. change in quality of life measured via the Work Productivity and Activity Impairment Questionnaire

    The Work Productivity and Activity Impairment Questionnaire ask about the effect of the participant's health problems on the ability to work and perform regular activities. A variety of question/response styles are included in the survey.

    Time frame: 3 Months

  6. change in quality of life measured via the Scored Patient-Generated Subjective Global Assessment

    The Score Patient-Generated Subjective Global Assessment asks about participant nutrition. A variety of question/response styles are included in the survey.

    Time frame: 3 Months

  7. change in quality of life measured via the EORTC questionnaire

    The EORTC Quality of life questionnaire asks a variety of questions about their health regarding physical abilities. Response options include: not at all; a little; quite a bit; very much.

    Time frame: 3 Months

  8. change in quality of life measured via the ECHO EXERT survey

    The Experience of Care and Health Outcomes (ECHO) Survey asks three questions about participant experience with the exercise intervention. Response options include: not at all; not much; mixed; somewhat; very much so.

    Time frame: 3 Months

  9. change in quality of life measured via the Health Belief Scale

    The Health Belief Scale asks questions regarding exercise therapy. Response options include: strongly disagree - strongly agree, where 1 equals strongly disagree and 4 equals strongly agree.

    Time frame: 3 Months

07

Study locations

1 site
  • Penn State Cancer Institute
    Hershey, Pennsylvania 17033, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 3, 2018
  • Informed consent form · Jan 15, 2018

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03905356
Lead sponsor
Milton S. Hershey Medical Center
Responsible party
Kathleen Sturgeon (Assistant Professor, Milton S. Hershey Medical Center) — Principal investigator
First posted
Apr 5, 2019
Start date
Feb 12, 2020
Primary completion
Jan 26, 2022
Completion
Jan 31, 2023
Last update
May 6, 2023

Study contacts

Kathleen Sturgeon, PhD
principal investigator · Penn State College of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion